By working together, we can help patients get better treatments, sooner.
Clario and the partner organization combine both organizations’ existing solutions to provide the customer with a more comprehensive product offering.
Clario and the partner organization contract to jointly enhance and deliver defined services. This level of deep integration extends beyond the product to touch other areas of business.
Clario and the partner organization work together to create and launch a new, unique product or service at the enterprise level.
Hear from our partners
Clario is renowned for delivering the reliable patient assessment data clinical trial sponsors need to confidently evaluate the safety and efficacy of new drug candidates. We’re pleased to collaborate with them as they expand their CNS measurement capabilities and leverage digital technologies to deliver more precise cognitive assessments, ultimately helping researchers bring new treatments to patients in need.
Brad O’Connor – CEO of Cogstate
When we started developing our product in 2015, we knew we needed feedback from customers and field experts, but our opportunity to get it was limited until Clario reached out to us. Just our initial meeting with them changed the course of our product development, and we continued to get Clario’s feedback at every step. Their knowledge and expertise in the respiratory area ultimately helped us secure our first investor. The biggest contribution they’ve made to us is close communication with their respiratory product team and the openness of our ongoing dialogue.
Kerem Yaşar – Co-Founder & CTO, Inofab Health
Clario’s experience in analyzing millions of ECGs and their dedication to patient safety makes them the gold standard in clinical trial cardiac safety assessment. We look forward to this partnership and to delivering the innovative solutions and valuable data that clinical trial sponsors require.
Priya Abani – CEO, AliveCor
We are delighted to partner with Clario and to work together in bringing these best-in-class offerings to patients and sponsors. As we make virtual trials the new reality, this partnership enables us to reduce patient burden and provide the high-quality data trial sponsors require as they evaluate the safety and efficacy of new medical treatments.
David Coman – Chief Executive Officer of Science 37